Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 11

SK pharmteco Invests $200M to Expand U.S. Drug Manufacturing

Oct 1, 2026
SK pharmteco has announced a five-year investment of more than $200 million to expand and upgrade its development and manufacturing operations in the U.S., with a focus on…
Read More...

AstraZeneca Invests $2B in Summit Therapeutics for Cancer Research

Oct 1, 2026
AstraZeneca has agreed to invest $2 billion in Summit Therapeutics to support the development of ivonescimab and explore new cancer treatment combinations involving antibody-drug…
Read More...

Varda Raises $251M to Scale Space-Based Pharmaceutical Manufacturing

Oct 1, 2026
Varda Space Industries has raised $251 million in a Series D financing round to expand its work in space-based pharmaceutical processing and move closer to producing medicines in space…
Read More...

Kyowa Kirin, Knight Therapeutics Expand Poteligeo Access in Latin America

Oct 1, 2026
Kyowa Kirin International has entered into an exclusive distribution agreement with Knight Therapeutics to expand access to Poteligeo (mogamulizumab) for patients with cutaneous T-cell…
Read More...

Atossa Plans CVRs Linked to Potential FDA Priority Review Voucher

Oct 1, 2026
Atossa Therapeutics has announced plans to issue contingent value rights (CVRs) to shareholders that could provide them with a share of proceeds from a potential future U.S. Food and…
Read More...

Profluent, BioMarin Partner on AI-Designed Enzyme Therapies

Oct 1, 2026
Profluent has entered into a collaboration with BioMarin Pharmaceutical to use artificial intelligence (AI) to design and optimize new enzyme therapies for BioMarin’s drug development…
Read More...

FDA Expands Camzyos Approval to Children With oHCM

Oct 1, 2026
The U.S. Food and Drug Administration (FDA) has expanded the approval of Bristol Myers Squibb’s Camzyos (mavacamten) to include pediatric patients with symptomatic obstructive…
Read More...

AbbVie, Valkai Partner to Advance AI in Clinical Development

Oct 1, 2026
AbbVie has entered into a new collaboration with life sciences AI company Valkai to expand the use of artificial intelligence across selected areas of clinical development. The…
Read More...

Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes

Sep 30, 2026
Novo Nordisk has reported new real-world data suggesting that adults with type 2 diabetes who increased their once-weekly semaglutide injection dose from 1 mg to 2 mg had a lower risk…
Read More...

Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy

Sep 30, 2026
Novo Nordisk has entered into a licensing agreement with Hengrui Pharma for HRS-1596, a Phase 1-ready oral drug candidate that targets both GLP-1 and GIP receptors. Under the…
Read More...
Previous 1 … 9 10 11 12 13 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.